Clinical trial
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
NCT00195572 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195572 |
|---|---|
| Title | Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer |
| Official title | Post-Approved Phase III Study of 1-LV/5FU Therapy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | Isovorin, TS-1 |
| Enrollment | 200 |
| Start date | May 1, 2002 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 13, 2009 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: